Literature DB >> 6986920

Elimination of acute myelogenous leukemic cells from marrow and tumor suspensions in the rat with 4-hydroperoxycyclophosphamide.

S J Sharkis, G W Santos, M Colvin.   

Abstract

Cell suspensions of normal rat marrow mixed with rat acute myelogenous leukemic cells were prepared and incubated in vitro with graded doses of 4-hydroperoxycyclophosphamide (4HC). The cell suspensions were injected into rats prepared with a lethal dose of total body irradiation. Animals injected with these cells survived fatal irradiation induced aplasia. In a dose related manner 4HC was able to "purge" tumor cells from the cell mixtures. Thus, animals given cell suspensions incubated with the lower doses of 4HC showed prolonged survival before death from leukemia and animals given cell suspensions incubated with higher doses of 4HC survival lethal irradiation without the subsequent appearance of leukemia. These studies clearly establish that tumor cells may be eliminated from normal marrow suspensions without completely destroying the pluripotent stem cells.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6986920

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  23 in total

Review 1.  Bone marrow purging with mafosfamide--a critical survey.

Authors:  H Sindermann; M Peukert; P Hilgard
Journal:  Blut       Date:  1989-11

Review 2.  Bone marrow transplantation. Part II--autologous.

Authors:  N J Chao; K G Blume
Journal:  West J Med       Date:  1990-01

Review 3.  Transferrin receptor: its biological significance.

Authors:  W S May; P Cuatrecasas
Journal:  J Membr Biol       Date:  1985       Impact factor: 1.843

4.  Haemopoietic stem cell autografts for leukaemia.

Authors:  J M Goldman
Journal:  Blut       Date:  1980-08

5.  Toxicity of ASTA Z 7557 (INN mafosfamide) to normal- and leukemic stem cells: implications for autologous bone marrow transplantation.

Authors:  A Hagenbeek; A C Martens
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

6.  ASTA Z 7557 (INN mafosfamide) for the in vitro treatment of human leukemic bone marrows.

Authors:  L Douay; N C Gorin; J P Laporte; M Lopez; A Najman; G Duhamel
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

7.  Autologous bone marrow transplantation for acute leukemia using transplant chemopurified with metabolite of oxazaphosphorines (ASTA Z 7557, INN mafosfamide). First clinical results.

Authors:  P Hervé; J Y Cahn; E Plouvier; M Flesch; E Tamayo; R Leconte des Floris; A Peters
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

8.  Comparative effects of ASTA Z 7557 (INN mafosfamide) and cyclophosphamide on hematopoiesis in mice.

Authors:  M R Nowrousian; C G Schmidt
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

9.  Preclinical pharmacokinetics and stability of isophosphoramide mustard.

Authors:  J J Zheng; K K Chan; F Muggia
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 10.  Cyclophosphamide and cancer: golden anniversary.

Authors:  Ashkan Emadi; Richard J Jones; Robert A Brodsky
Journal:  Nat Rev Clin Oncol       Date:  2009-09-29       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.